Group 1 - The Hang Seng Index rose by 0.65%, gaining 165 points to close at 25,663 points, while the Hang Seng Tech Index increased by 1.14% [1] - New listings in the Hong Kong stock market included Zhihui Mining (02546), which surged over 110% on its debut, and Xidi Zhijia (03881), which fell over 8% [1] - The U.S. Senate passed a revised version of the Biological Safety Act as part of the 2026 National Defense Authorization Act, leading to a significant rebound in pharmaceutical stocks, with WuXi Biologics (02269) rising over 6% and 3SBio (01530) increasing by 3.7% [1] Group 2 - HAP Pharmaceutical-B (02142) saw a nearly 7% increase after signing a BD deal worth over $1 billion with Bristol-Myers Squibb [2] - China Duty Free Group (01880) rebounded nearly 7% after winning bids for duty-free projects at two major airports in Shanghai, with market attention on the results of the capital airport bidding [3] Group 3 - Youjia Innovation (02431) rose over 12% as L3 large-scale deployment approaches, with the company strategically positioning itself for L2+L4 technologies [4] - Nine Dragons Paper (02689) increased over 3% as the industry leader announced a series of shutdown plans to support price and inventory levels before the Spring Festival [4] Group 4 - Southern Manganese (01091) rose over 9% due to multiple factors driving the continuous increase in electrolytic manganese prices [5] - Changfei Optical Fiber and Cable (06869) surged over 10%, with a cumulative increase of over 30% in the past three days, driven by AI demand for optical fiber and cable [6] - Ganwan (09890) increased over 5% after issuing zero-coupon convertible bonds at a premium, raising HKD 450 million to enhance its "AI + gaming" strategy [7] - Likun Resources (02245) rose over 9% as Indonesia plans to significantly reduce its nickel ore production targets by 2026 [8] - Shenzhou International (02313) fell over 3% as its major client Nike reported a 32% year-on-year decline in net profit for the second fiscal quarter [9]

Market Performance - The Hang Seng Index increased by 0.65% and the Hang Seng Tech Index rose by 1.14% [1] - The Hong Kong Tech ETF (159751) gained 1.76%, while the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 1.02% [1] Sector Performance - The life sciences tools and automotive parts sectors showed the highest gains [1] - The media, forestry, and paper products sectors experienced the largest declines [1] Individual Stock Movements - Zhihui Mining surged over 111% [1] - China Duty Free Group rose by 7.56%, Horizon Robotics (W) increased by 7.16%, WuXi Biologics gained 6.48%, and Xpeng Motors (W) was up by 5.69% [1] - Shenzhou International fell by 3.89% and China National Heavy Duty Truck Group dropped by 5.71% [1] - Youjia Innovation increased by 12.13% and CIMC (China International Marine Containers) rose by 11.96% [1]

Group 1: Policy and Regulatory Developments - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)" and the "Commercial Health Insurance Innovative Drug Catalog (2025)", effective from January 1, 2026, nationwide [1] - The medical insurance catalog adds 114 new drugs, including 50 innovative first-class drugs, with an overall success rate of 88%, a 12 percentage point increase from 2024 [1] - The first version of the commercial health insurance innovative drug catalog includes 19 drugs, marking a significant breakthrough in the "medical insurance + commercial insurance" multi-layered medical security system [1] Group 2: Market Trends and Investment Opportunities - The Chinese innovative drug sector is experiencing active out-licensing (BD) transactions, with a total transaction amount exceeding $92 billion and 103 deals completed in the first three quarters of 2025, indicating strong international recognition of Chinese R&D achievements [2] - The innovative drug R&D is entering a harvest period, with pipeline values gradually being realized, supported by overseas payment capabilities and a shift towards hard-core technology-driven growth [2] - Emerging technologies such as small nucleic acids, in vivo CAR-T, and AI drug development platforms are expected to see a clinical value explosion, while the CXO industry remains robust, benefiting from new tracks like ADC, peptides, and CGT [2] Group 3: ETF Performance and Market Sentiment - As of December 18, 2025, the Hong Kong innovative drug ETF (513120) has seen a strong increase of 10.56% over the past six months, with significant contributions from major stocks like WuXi Biologics and 3SBio [3] - The latest scale of the Hong Kong innovative drug ETF reached 24.322 billion yuan, making it the largest in the Hong Kong market for pharmaceutical ETFs, with a net inflow of 327 million yuan over the past five trading days [3] - The innovative drug ETF (515120) also experienced a rise, with major stocks like Zai Lab and WuXi AppTec contributing to the gains, indicating a positive market sentiment towards innovative drug investments [4]

Group 1 - The core viewpoint of the article highlights a rebound in two major sectors of Hong Kong stocks: internet and innovative pharmaceuticals, with the Hong Kong Stock Connect Technology ETF (159101.SZ) rising by 1.5% [1] - Key stocks such as WuXi Biologics increased by over 6%, and WuXi AppTec rose by over 4%, while Tencent, Meituan, and Alibaba experienced slight increases [1] - After three months of adjustment, the crowdedness in these two core sectors has returned to low levels, with recent catalysts for growth including Tencent's release of the mixed reality model and Baidu's Kunlun chip accelerating towards an IPO, projected to exceed 2 billion yuan in revenue by 2025 [1] Group 2 - The passing of the U.S. National Defense Authorization Act for fiscal year 2026 on December 18 is seen as beneficial for CXO companies like WuXi Biologics and WuXi AppTec, as the new version of the biosafety law does not specifically name any companies [1] - Improved relations between the two countries have also boosted market risk appetite [1] - The Hong Kong Stock Connect Technology ETF (159101.SZ) tracks the National Index for Hong Kong Stock Connect Technology, which has reduced exposure to consumer retail while increasing allocation to biopharmaceuticals and hardware equipment, allowing for greater index elasticity [1]

Core Insights - The article highlights the performance of the Tianhong Innovation Drug ETF (517380), which has seen a trading volume of 14.27 million yuan and a nearly 3% increase in the tracked Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID) [1] - The article discusses a new three-year enhancement plan for the biopharmaceutical industry in Xi'an, indicating a new policy support cycle for the innovative drug sector [1][2] Product Highlights - The Tianhong Innovation Drug ETF (517380) spans the Shanghai, Hong Kong, and Shenzhen markets, selecting 50 leading innovative drug companies, with 40% from Hong Kong and 60% from A-shares, covering core areas such as biopharmaceuticals and chemical pharmaceuticals [1] - Related products include the Tianhong Innovation Drug ETF and its corresponding off-market connection funds (Class A: 014564, Class C: 014565) [1] Industry Developments - Xi'an's government has released an implementation plan for 2025-2027, aiming to achieve breakthroughs in key drug development technologies in areas such as stem cell drugs, peptide drugs, liver-targeted innovative drugs, and anesthetics [2] - By 2027, Xi'an aims to have one clinically approved drug and one production-approved drug in the innovative drug R&D field, along with 40 Class III and 400 Class II medical devices approved [2] - The innovative drug sector is entering a new policy support cycle, with various cities like Beijing and Shanghai implementing supportive policies for the pharmaceutical and health industry [2] Institutional Perspectives - Zhongtai Securities views innovative drugs as the most important theme in the pharmaceutical sector, noting that the recent 2-3 month market adjustment has brought stock prices, market expectations, and capital allocation back to relatively reasonable and low levels, highlighting investment safety margins and return value [2]

Group 1 - Hong Kong pharmaceutical stocks showed a significant rebound this morning, particularly in the CRO and innovative drug sectors [1] - Kelaiying (06821.HK) increased by 6.28%, reaching HKD 77 [1] - WuXi Biologics (02269.HK) rose by 6.11%, trading at HKD 34.72 [1] - Sangfor Pharmaceuticals (01530.HK) gained 5.04%, priced at HKD 26.68 [1] - Innovent Biologics (09969.HK) saw an increase of 4.25%, with shares at HKD 13.74 [1]

Group 1 - Pharmaceutical stocks showed a significant rebound, with CRO and innovative drug sectors leading the way. Notable stock performances include Kelaiying (002821) up 6.28% to 77 HKD, WuXi Biologics (02269) up 6.11% to 34.72 HKD, and Sangfor Technologies (01530) up 5.04% to 26.68 HKD [1] - The U.S. Senate passed the revised version of the Biological Safety Act as part of the 2026 National Defense Authorization Act (2026 NDAA), which is seen as a positive development for the industry, although it does not specifically name any companies [1] - According to Industrial Securities, the recent decline in the innovative drug sector is expected to be temporary, with the sector's outlook remaining positive due to ongoing business development (BD) activities. The trend of "innovation + internationalization" in the innovative drug industry is expected to continue [1] Group 2 - The innovative drug industry chain is showing signs of improvement in fundamentals, with positive trends observed in investment and financing data, orders, and performance metrics [1]

Group 1 - Pharmaceutical stocks showed a significant rebound today, particularly in the CRO and innovative drug sectors [1][3] - Companies such as Kelaiying (06821) saw an increase of 6.07%, trading at 76.85 HKD [1][3] - WuXi Biologics (02269) rose by 6.05%, reaching 34.70 HKD [1][3] - Sangfor Pharmaceuticals (01530) increased by 4.65%, priced at 26.58 HKD [1][3] - Innovent Biologics (09969) experienced a rise of 4.70%, trading at 13.80 HKD [1][3]

Core Viewpoint - The Hong Kong technology sector experienced a rebound on December 19, with significant gains in biotechnology stocks, particularly benefiting from the recent passage of the 2026 National Defense Authorization Act (2026 NDAA) in the U.S. [1] Group 1: Market Performance - The Hang Seng Biotechnology and Hong Kong Stock Connect Technology Indexes led the gains, with WuXi Biologics rising over 5% and WuXi AppTec increasing more than 4% [1] - Other notable performers included Innovent Biologics and CanSino Biologics, both of which saw increases exceeding 2% [1] Group 2: Regulatory Impact - The new version of the U.S. bioterrorism law did not specifically name any companies, which is seen as a significant positive for Chinese CXO companies, including WuXi AppTec and WuXi Biologics, that have been under pressure from previous regulations [1] Group 3: Investment Opportunities - There are low-positioning opportunities in related ETFs covering Hong Kong CXO leaders, specifically the Hang Seng Pharmaceutical ETF (159892.SZ) and the Hong Kong Stock Connect Technology ETF (159101.SZ) [1]

兴业证券认为，近期创新药板块情绪回落，随着BD持续落地，该行认为当前板块景气度可持续，"创新 +国际化"创新药产业趋势不变，短期调整后创新药板块弹性进一步提升。同时，可继续重点关注基本 面已开始改善的创新药产业链，当前在投融资数据、订单和业绩层面均看到向好趋势。 消息面上，据券商中国日前报道，北京时间12月18日凌晨，参议院官网显示，搭载修订版《生物安全法 案》的美国2026财年国防授权法案（2026NDAA）获通过。新版本生物安全法未具体点名任何一家公 司。有券商研究机构认为，2025年法案进展阶段性落地，行业回归中长期增量逻辑。 智通财经APP获悉，医药股今早明显反弹，CRO、创新药方向居前。截至发稿，凯莱英(06821)涨 6.28%，报77港元；药明生物(02269)涨6.11%，报34.72港元；三生制药(01530)涨5.04%，报26.68港元； 诺诚健华(09969)涨4.25%，报13.74港元。 ...